Social Capital Suvretta Holdings Corp. III (DNAC)
Price:
9.28 USD
( - -0.72 USD)
Your position:
0 USD
ACTION PANEL
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Churchill Capital Corp X
VALUE SCORE:
7
2nd position
Range Capital Acquisition Corp.
VALUE SCORE:
10
The best
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Social Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada.
NEWS
ProKidney to present at upcoming investor conferences
globenewswire.com
2022-05-20 09:00:00WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced that Tim Bertram, PhD, Chief Executive Officer, will present at the following investor conferences:
ProKidney to Present REACT® at 4th Annual CKD Summit
globenewswire.com
2022-03-01 08:05:00WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company's lead product candiate, Renal Autologous Cell Therapy (REACT®) at the 4th Annual CKD Summit, being held March 1-3, 2022 in Boston, MA.
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
pulse2.com
2022-01-18 15:03:37ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
benzinga.com
2022-01-18 13:56:12ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III (NASDAQ: DNAC) in a deal valuing the combined entity at $2.64 billion. ProKidney first made waves in 2019, when it disclosed the $62 million acquisition of inRegen and raised $75 million to fund the deal and another takeover.
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
marketwatch.com
2022-01-18 07:45:58ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC, +0.19% in a deal that values the combined company at $2.64 billion. The deal, which will take ProKidney public, is expected to provide $825 million in cash proceeds.
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
benzinga.com
2022-01-09 17:24:23The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.
No data to display
ProKidney to present at upcoming investor conferences
globenewswire.com
2022-05-20 09:00:00WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced that Tim Bertram, PhD, Chief Executive Officer, will present at the following investor conferences:
ProKidney to Present REACT® at 4th Annual CKD Summit
globenewswire.com
2022-03-01 08:05:00WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company's lead product candiate, Renal Autologous Cell Therapy (REACT®) at the 4th Annual CKD Summit, being held March 1-3, 2022 in Boston, MA.
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
pulse2.com
2022-01-18 15:03:37ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
benzinga.com
2022-01-18 13:56:12ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III (NASDAQ: DNAC) in a deal valuing the combined entity at $2.64 billion. ProKidney first made waves in 2019, when it disclosed the $62 million acquisition of inRegen and raised $75 million to fund the deal and another takeover.
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
marketwatch.com
2022-01-18 07:45:58ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC, +0.19% in a deal that values the combined company at $2.64 billion. The deal, which will take ProKidney public, is expected to provide $825 million in cash proceeds.
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
benzinga.com
2022-01-09 17:24:23The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.